Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE N/A. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.0B | $129M | $76M | $151M | $263M | $432M | — | — | — |
| Enterprise Value | $621M | $-264361993 | $26M | $155M | $244M | $330M | — | — | — |
| P/E Ratio → | -0.27 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 0.79 | 1.00 | 1.05 | 2.00 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -94.5% | -58.7% | -39.5% | -52.1% | -155.0% | -2483.2% | — |
| ROA | -229.3% | -229.3% | -66.3% | -46.3% | -34.0% | -43.3% | -101.1% | -200.1% | -412.3% |
| ROIC | — | — | -90.2% | -48.9% | -40.5% | -78.1% | -338.8% | — | — |
| ROCE | -132.0% | -132.0% | -76.1% | -52.5% | -36.0% | -46.3% | -118.3% | -2386.5% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.33 | 0.24 | 0.16 | 0.08 | 0.38 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.52 | 0.03 | -0.07 | -0.47 | -0.63 | -0.85 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -16.83 | -3.14 |
Net cash position: cash ($396M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.20 | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Quick Ratio | 18.20 | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Cash Ratio | 18.08 | 18.08 | 4.94 | 8.81 | 17.55 | 20.43 | 4.76 | 2.96 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $10M | $3M | $3M | $2M | $2M | $2M | $2M | $283024 |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VOR stock.
Vor Biopharma Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Based on historical data, Vor Biopharma Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Clinical trial execution risk
Metrics are mathematically derived from official filings.
Cash Buffer Masks Equity Erosion
Vor's current ratio remains exceptionally high at 19.15 in 2026Q2, but cash fell 73% from $396.5M to $107.9M, per balance sheet data, signaling a rapidly shrinking runway.
The current ratio, while superficially strong, is driven by a cash pile that is depleting quickly. The 73% decline in cash from 2025Q4 to 2026Q2, as reported in financial statements, suggests that the liquidity cushion is eroding faster than the ratio implies. Investors should monitor whether the company can secure additional financing before the cash runway shortens further.
Negative Returns Reflect Pre-Revenue Burn
ROIC deteriorated from -18.1% in 2024Q1 to -53.5% in 2025Q1, per reported figures, indicating escalating capital consumption without any revenue generation.
The negative and worsening ROIC is a direct consequence of the pre-revenue model, where R&D spending is the sole driver of capital deployment. The sharp decline in ROIC over the past year suggests that the company is investing heavily in clinical trials, but the returns are not yet visible. This trend is typical for clinical-stage biotechs, but the magnitude of the negative returns highlights the high risk of capital destruction if clinical milestones are not met.
Working Capital Swings Signal Trial Timing
DPO swung from 152 days in 2024Q4 to 9,916 days in 2026Q1, per financial statements, indicating extreme volatility in payment timing that obscures true working capital efficiency.
The erratic DPO figures, ranging from 150 to nearly 10,000 days, suggest that the company's payables are heavily influenced by the timing of clinical trial invoices and collaboration payments. This volatility makes it difficult to assess the company's true negotiating power with suppliers. The lack of consistent DSO and DIO data further complicates any meaningful analysis of the cash conversion cycle, which remains undefined.
Minimal Debt, Negative Equity
Vor's debt is negligible at $2.9M in 2026Q2, but stockholders' equity turned negative at -$200.2M, per balance sheet data, making the D/E ratio undefined.
The company's low debt levels suggest that it has not relied on leverage to fund operations, but the negative equity position indicates that cumulative losses have exceeded capital raised. This negative equity is a red flag for creditors and investors, as it implies that the company is technically insolvent on a book value basis. However, the negative equity is heavily influenced by non-cash charges, such as stock-based compensation, which may not reflect the true economic deterioration.
Valuation Gap Reflects Binary Risk
Vor's P/E of -0.33 is far less negative than peers like BEAM (-33.15) and CRSP (-8.36), per market data, suggesting the market prices Vor for a higher probability of failure.
The less negative P/E multiple for Vor, compared to its gene-editing peers, implies that the market assigns a lower valuation to its earnings power, which is currently non-existent. This could be due to the binary nature of Vor's clinical trials, where success or failure of VOR33 will determine the company's future. The peer comparison also shows that Vor's ROE and ROIC are more negative than most peers, indicating a higher burn rate relative to its capital base.
Misapplied P/E on Pre-Revenue Model
The P/E ratio is commonly misapplied to Vor, as it has no earnings; a more relevant metric is cash runway, which at $107.9M suggests roughly 2-3 years of funding, per financial data.
Using P/E for a pre-revenue biotech is meaningless because the denominator is negative and the metric does not capture the company's true value drivers, such as clinical trial progress and cash runway. Instead, investors should focus on the cash burn rate and the time to key data readouts. With $107.9M in cash and an average quarterly burn of around $35M, Vor has approximately 2-3 years of runway, but this could be shortened if R&D spending spikes as seen in 2025Q2.